A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder.

BACKGROUND Cranial electrotherapy stimulation (CES) is a noninvasive procedure that has been used for decades in the United States to treat anxiety, depression, and insomnia in the general population. Whether CES is an effective treatment for patients with a DSM-IV diagnosis of generalized anxiety disorder (GAD) has not previously been explored. The goal of this study was to evaluate the efficacy of CES in alleviating anxiety in patients with DSM-IV-diagnosed GAD. METHOD Twelve patients from 29 to 58 years of age with a DSM-IV diagnosis of GAD were enrolled from August 2005 to March 2006 through the University of California, Los Angeles (UCLA) Anxiety Disorders Program. Cranial electrotherapy stimulation treatment was administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity. The primary efficacy measures were the Hamilton Rating Scale for Anxiety (HAM-A) and the Clinical Global Impressions-Improvement (CGI-I) scale. Response to treatment was defined as a reduction of 50% or more on the HAM-A and a CGI-I score of 1 or 2 ("much improved" or "very much improved," respectively). RESULTS Cranial electrotherapy stimulation was associated with a significant decrease in HAM-A scores (t = 3.083, p = .01). At endpoint, 6 patients (50% of the intent-to-treat sample and 67% of completers) had a 50% decrease in HAM-A score and a CGI-I score of 1 or 2. One additional patient significantly improved in anxiety scores but did not meet criteria for response. Adverse events were generally mild in severity, mostly consisting of headache and nausea. CONCLUSION This preliminary study suggests that CES may reduce symptoms of anxiety in GAD. We hope that these preliminary results will encourage further research to explore the use of CES in clinical settings. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00539357.

[1]  Jennifer Corns The placebo effect , 2018, Philosophy of Pain.

[2]  T. Müller,et al.  Anxiolytic effect of rescue remedy for psychiatric patients: a double-blind, placebo-controlled, randomized trial. , 2006, Journal of clinical psychopharmacology.

[3]  K. Vonck,et al.  Vagus nerve stimulation and cognition , 2006, Seizure.

[4]  C. Sherbourne,et al.  Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders. , 2005, General hospital psychiatry.

[5]  Tor D. Wager,et al.  Expectations and anxiety as mediators of placebo effects in pain , 2005, Pain.

[6]  D. Stein,et al.  Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram , 2004, BMC psychiatry.

[7]  Rudolf Hoehn-Saric,et al.  Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. , 2004, Archives of general psychiatry.

[8]  C. Shealy,et al.  Transcutaneous electrical nerve stimulation: the treatment of choice for pain and depression. , 2003, Journal of alternative and complementary medicine.

[9]  M. Tansella,et al.  Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. , 2003, Journal of affective disorders.

[10]  D. Sheehan,et al.  Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.

[11]  J. Leite,et al.  Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo‐controlled pilot study , 2002, Phytotherapy research : PTR.

[12]  R. Kessler,et al.  Patterns and correlates of generalized anxiety disorder in community samples. , 2002, The Journal of clinical psychiatry.

[13]  R. E. Barr,et al.  Quantitative analysis of the electroencephalogram during cranial electrotherapy stimulation , 2001, Clinical Neurophysiology.

[14]  M. Pollack,et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.

[15]  R. Kessler,et al.  The epidemiology of generalized anxiety disorder. , 2001, The Psychiatric clinics of North America.

[16]  K. Rickels,et al.  Overview and clinical presentation of generalized anxiety disorder. , 2001, The Psychiatric clinics of North America.

[17]  R. Kessler,et al.  The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research , 2000, Acta psychiatrica Scandinavica. Supplementum.

[18]  S. Beck,et al.  Folinic acid reduces cleft lip [CL(P)] in A/WySn mice. , 1999, Teratology.

[19]  J. Matson,et al.  Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS). , 1998, Research in developmental disabilities.

[20]  G. Emilien,et al.  Use of a placebo in clinical trials , 1998, European Psychiatry.

[21]  A. Schatzberg,et al.  Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders , 1998, British Journal of Psychiatry.

[22]  T. Baghai,et al.  Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients , 1998, Psychopharmacology.

[23]  R. Lydiard,et al.  Biological basis of generalized anxiety disorder. , 1997, The Journal of clinical psychiatry.

[24]  F. X. Bostick,et al.  Potential and current density distributions of cranial electrotherapy stimulation (CES) in a four-concentric-spheres model , 1996, IEEE Transactions on Biomedical Engineering.

[25]  K. Rickels,et al.  Placebo‐controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder , 1995, International clinical psychopharmacology.

[26]  T. Chalmers,et al.  Meta‐Analysis of Randomized Controlled Trials of Cranial Electrostimulation: Efficacy in Treating Selected Psychological and Physiological Conditions , 1995, The Journal of nervous and mental disease.

[27]  J. Yager,et al.  Psychometric discrimination between anxiety and depression. , 1993, The Journal of nervous and mental disease.

[28]  D. Shapiro,et al.  Continuous physiological changes and subjective reports in panic patients: A preliminary methodological report , 1992, Biological Psychiatry.

[29]  F. Okada “Reverse Placebo Effects”: Anticipation/Anxiety at the Possibility of Receiving Placebos , 1992, The Annals of pharmacotherapy.

[30]  Monte S. Buchsbaum,et al.  PET in generalized anxiety disorder , 1991, Biological Psychiatry.

[31]  J. Vincent,et al.  Efficiency of transcranial electrostimulation on anxiety and insomnia symptoms during a washout period in depressed patients a double-blind study , 1991, Biological Psychiatry.

[32]  S. Solomon,et al.  Safety and Effectiveness of Cranial Electrotherapy in the Treatment of Tension Headache , 1989, Headache.

[33]  R. Noyes,et al.  Generalized anxiety disorder. , 1987, Primary care.

[34]  M S Buchsbaum,et al.  Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. , 1987, Life sciences.

[35]  E. Boyd,et al.  Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons. , 1986, Alcoholism, clinical and experimental research.

[36]  W. B. Jarzembski Electrical stimulation and substance abuse treatment. , 1985, Neurobehavioral toxicology and teratology.

[37]  H. Frazier,et al.  Cranial electrotherapy stimulation treatment of cognitive brain dysfunction in chemical dependence. , 1984, The Journal of clinical psychiatry.

[38]  W. Guy Patient assessment in clinical trials , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  C. S. Mellor,et al.  A double-blind study of electrosleep for anxiety and insomnia. , 1975, Biological psychiatry.

[40]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[41]  M. Segal,et al.  A clinical comparison study of the effects of reserpine and placebo on anxiety. , 1959, A.M.A. archives of neurology and psychiatry.

[42]  M. Hamilton The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[43]  M. Fenichel,et al.  Electrosleep therapy in psychoses. , 1957, Diseases of the nervous system.

[44]  E. Arian [Electrosleep; clinical experiences]. , 1957, Minerva medica.

[45]  J. Davidson,et al.  Pharmacotherapy of generalized anxiety disorder. , 2001, The Journal of clinical psychiatry.

[46]  M. Pollack Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. , 2001, The Journal of clinical psychiatry.

[47]  Daniel L. Kirsch,et al.  The use of cranial electrotherapy stimulation in the management of chronic pain: A review. , 2000, NeuroRehabilitation.

[48]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[49]  A. Bystritsky,et al.  Four-dimensional Anxiety and Depression Scale: a preliminary psychometric report. , 1996, Anxiety.

[50]  J. Marshall,et al.  The use of cranial electrotherapy stimulation in the treatment of closed-head-injured patients. , 1994, Brain injury.

[51]  V P Lebedev,et al.  The administration of transcranial electric treatment for affective disturbances therapy in alcoholic patients. , 1991, Drug and alcohol dependence.

[52]  A. Flemenbaum Cerebral electrotherapy (electrosleep): a review. , 1975, Current psychiatric therapies.

[53]  A. Flemenbaum Cerebral electrotherapy (electrosleep): an open-clinical study with a six month follow-up. , 1974, Psychosomatics.

[54]  Electrosleep and cerebral electrotherapy. , 1971, The Medical letter on drugs and therapeutics.

[55]  R. C. Long Electrosleep therapy. Some results with the use of electrically induced sleep in the treatment of psychiatric patients. , 1966, The Journal of the Kansas Medical Society.